Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Y.S.P. Southeast Asia Holding Bhd's Debt-to-EBITDA or its related term are showing as below:
XKLS:7178'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.47 Med: 0.81 Max: 1.38
Current: 1.38
During the past 13 years, the highest Debt-to-EBITDA Ratio of Y.S.P. Southeast Asia Holding Bhd was 1.38. The lowest was 0.47. And the median was 0.81.
XKLS:7178's Debt-to-EBITDA is ranked better than 53.43% of 685
companies
in the Drug Manufacturers industry
Industry Median: 1.58
vs XKLS:7178: 1.38
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Y.S.P. Southeast Asia Holding Bhd Debt-to-EBITDA Related Terms
Y.S.P. Southeast Asia Holding Bhd Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y.S.P. Southeast Asia Holding Bhd Debt-to-EBITDA Chart
XKLS:7178 vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Y.S.P. Southeast Asia Holding Bhd's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y.S.P. Southeast Asia Holding Bhd Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Y.S.P. Southeast Asia Holding Bhd's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Y.S.P. Southeast Asia Holding Bhd's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) has a Debt-to-EBITDA of 0.90 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Y.S.P. Southeast Asia Holding Bhd. This is 11% above median its historical median of 0.81. Over the past decade, Y.S.P. Southeast Asia Holding Bhd's Debt-to-EBITDA has ranged from 0.47 to 1.38. According to the industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #319 out of 685 companies in the Drug Manufacturers industry, placing it in the top 46.6%.
Is Y.S.P. Southeast Asia Holding Bhd's Debt-to-EBITDA too high?
Y.S.P. Southeast Asia Holding Bhd's current Debt-to-EBITDA of 0.90 is 11% above median its 10-year median of 0.81. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 1.38. The Drug Manufacturers industry median Debt-to-EBITDA is 1.58. Y.S.P. Southeast Asia Holding Bhd's value of 0.90 is 43% below this industry median. Based on the distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #319 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Y.S.P. Southeast Asia Holding Bhd has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Y.S.P. Southeast Asia Holding Bhd's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #319 out of 685 companies for Debt-to-EBITDA. This puts Y.S.P. Southeast Asia Holding Bhd in the upper half of its industry. The industry median Debt-to-EBITDA is 1.58. Y.S.P. Southeast Asia Holding Bhd's value of 0.90 is 43% below this benchmark. Historically, Y.S.P. Southeast Asia Holding Bhd's own Debt-to-EBITDA has ranged from 0.47 to 1.38 over the past decade. While the company's 10-year median is 0.81 vs. the industry median of 1.58, Y.S.P. Southeast Asia Holding Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.58, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Y.S.P. Southeast Asia Holding Bhd's current Debt-to-EBITDA of 0.90 is 43% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Y.S.P. Southeast Asia Holding Bhd. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Y.S.P. Southeast Asia Holding Bhd's current Debt-to-EBITDA is 0.90, which is 11% above median its own 10-year median of 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Y.S.P. Southeast Asia Holding Bhd stock overvalued right now?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) is currently considered Modestly Undervalued. The stock's GF Value™ is RM2.41, compared to a current price of RM2.01 — trading 16.6% below its estimated fair value. The current Debt-to-EBITDA is 0.90, which is 11% above median its 10-year median of 0.81 and 43% below the Drug Manufacturers industry median of 1.58. Y.S.P. Southeast Asia Holding Bhd's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Y.S.P. Southeast Asia Holding Bhd (XKLS:7178), the current Debt-to-EBITDA is 0.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) Overvalued in 2026?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd stock appears to be undervalued.
The current stock price of RM2.01 is trading 16.6% below its estimated GF Value™ of RM2.41.
GuruFocus considers Y.S.P. Southeast Asia Holding Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7178:
Debt-to-EBITDA: 0.90 (11% above median its 10-year median of 0.81)
GF Value™: RM2.41 vs. price of RM2.01 (16.6% below fair value)
Industry Position: 43% below the Drug Manufacturers median (#319 of 685)
No single metric tells the full story. See the XKLS:7178 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Y.S.P. Southeast Asia Holding Bhd is an investment company, that engages in the pharmaceutical business, and provision of management services. The company operates through the following segments: Trading, Manufacturing, and Investment Holding. The Trading segment imports, exports, and trading in various kinds of pharmaceutical products, and traditional herbal and veterinary products. The Manufacturing segment manufactures pharmaceutical products. The Investment Holding segment focuses on investment holding activity. The firm's majority of revenue comes from the Manufacturing segment. The majority of revenue is derived from Malaysia.
69GF Score
Get the complete analysis for XKLS:7178
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7178 has been successfully added to your 
